At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 68 enrolled
Drug / intervention
Taurolidine Urokinase +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prevention of Tunneled Cuffed Catheter Malfunction With Prophylactic Use of a Taurolidine Locking Solution Containing Urokinase : a Multicentric Randomized Controlled Trial
In Brief
A Phase 3 clinical trial evaluating Taurolidine Urokinase and Taurolidine Heparin for Patency and Infection. Completed, enrolled 68 participants across 9 sites.
Detailed Summary
The objective of our study is to investigate whether the substitution of the standard locking solution with a locking solution containing taurolidine and urokinase weekly (Taurolock ™ U 25,000 - www.taurolock.com ) reduces the rate of catheter dysfunction in hemodialysis patients with a history of TCC dysfunction requiring urokinase therapy.
Study Details
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartMay 2015
Primary CompletionJul 2017
Study CompletionMay 2018
TodayJul 2026
First PostedJan 14, 2014
Enrollment StartMay 1, 2015
Primary CompletionJul 1, 2017
Study CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 12.5 years ago
Interventions
Taurolidine Urokinasedrug
Taurolidine Heparindrug